{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:03:58Z","timestamp":1788635038336,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2K12CA138464"],"award-info":[{"award-number":["2K12CA138464"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA093373"],"award-info":[{"award-number":["P30CA093373"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.semnephrol.2019.12.009","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T18:59:53Z","timestamp":1582570793000},"page":"76-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Mamta","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poornima","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2019.12.009_bib0001","first-page":"14","article-title":"A phase II study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression","volume":"1","author":"Oliver","year":"1988","journal-title":"Mol Biother"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0002","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1464-410X.1989.tb05147.x","article-title":"Unexplained spontaneous regression and alpha interferon as treatment for metastatic renal cell carcinoma","volume":"63","author":"Oliver","year":"1989","journal-title":"Br J Urol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0003","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0022-5347(17)36874-X","article-title":"Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup","volume":"148","author":"Vogelzang","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0004","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000658-199809000-00004","article-title":"Duration of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response","volume":"228","author":"Rosenberg","year":"1998","journal-title":"Ann Surg"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0006","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0007","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJM200112063452317","article-title":"Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma","volume":"345","author":"Pantuck","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0008","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0009","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0011","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00109-003-0430-2","article-title":"B7-H1 pathway and its role in the evasion of tumor immunity","volume":"81","author":"Dong","year":"2003","journal-title":"J Mol Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0012","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0013","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0014","doi-asserted-by":"crossref","first-page":"s4500","DOI":"10.1200\/JCO.2018.36.15_suppl.4500","article-title":"Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427 [abstract]","volume":"36","author":"McDermott","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0016","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0017","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0018","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0019","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0020","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion 151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0021","doi-asserted-by":"crossref","first-page":"s4506","DOI":"10.1200\/JCO.2017.35.15_suppl.4506","article-title":"A phase I\/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC) [abstract]","volume":"35","author":"Chowdhury","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0022","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0023","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0024","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase Ib trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0026","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0027","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0028","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0029","doi-asserted-by":"crossref","first-page":"s515","DOI":"10.1200\/JCO.2018.36.6_suppl.515","article-title":"Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies [abstract]","volume":"36","author":"Nadal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs- part a: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0031","doi-asserted-by":"crossref","unstructured":"Lee JL, Ziobro M, Gafanov R, Matveev VB, Suarez C, Donskov F, et al. KEYNOTE-427 cohort B: first-line pembrolizumab (pembro) monotherapy for advanced non-clear renal cell carcinoma (NCC-RCC) [abstract]. J Clin Oncol. 2019;37:s4569.","DOI":"10.1200\/JCO.2019.37.15_suppl.4569"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0032","doi-asserted-by":"crossref","first-page":"s562","DOI":"10.1200\/JCO.2019.37.7_suppl.562","article-title":"Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): results from the phase IIIb\/IV CheckMate 374 study [abstract]","volume":"37","author":"Vogelzang","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0033","doi-asserted-by":"crossref","first-page":"s548","DOI":"10.1200\/JCO.2019.37.7_suppl.548","article-title":"Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with sarcomatoid differentiation [abstract]","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0034","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.urolonc.2017.12.012","article-title":"Sarcomatoid renal cell carcinoma: biology and treatment advances","volume":"36","author":"Mouallem","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/2326-6066.CIR-17-0475","article-title":"The clinical activity of PD-1\/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma","volume":"6","author":"McKay","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0036","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0037","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng1020","article-title":"A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans","volume":"32","author":"Prokunina","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0038","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0039","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small cell lung cancer","volume":"28","author":"Osario","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0040","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1073\/pnas.1415675112","article-title":"Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis","volume":"112","author":"Harbour","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0041","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Posto","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0042","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0043","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0044","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0045","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2326-6066.CIR-17-0220","article-title":"Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1\/PD-L1 therapy for immune-related adverse events","volume":"6","author":"Martini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0046","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0047","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/17512433.2019.1613888","article-title":"The nephrotoxicity of new immunotherapies","volume":"12","author":"Sury","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2019.12.009_bib0048","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929519301196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929519301196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:22:49Z","timestamp":1777540969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929519301196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0270929519301196"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2019.12.009","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2019.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}